Cite
BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
MLA
Rosa, Regis Goulart, et al. “BNT162b2 MRNA COVID-19 against Symptomatic Omicron Infection Following a Mass Vaccination Campaign in Southern Brazil: A Prospective Test-Negative Design Study.” Vaccine, vol. 41, no. 37, Aug. 2023, pp. 5461–68. EBSCOhost, https://doi.org/10.1016/j.vaccine.2023.07.038.
APA
Rosa, R. G., Falavigna, M., Manfio, J. L., de Araujo, C. L. P., Cohen, M., do Valle Barbosa, G. R. G., de Souza, A. P., Romeiro Silva, F. K., Sganzerla, D., da Silva, M. M. D., Ferreira, D., de Oliveira Rodrigues, C., de Souza, E. M., de Oliveira, J. C., Gradia, D. F., Brandalize, A. P. C., Royer, C. A., Luiz, R. M., Kucharski, G. A., … McLaughlin, J. M. (2023). BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study. Vaccine, 41(37), 5461–5468. https://doi.org/10.1016/j.vaccine.2023.07.038
Chicago
Rosa, Regis Goulart, Maicon Falavigna, Josélia Larger Manfio, Cintia Laura Pereira de Araujo, Mírian Cohen, Gynara Rezende Gonzalez do Valle Barbosa, Ana Paula de Souza, et al. 2023. “BNT162b2 MRNA COVID-19 against Symptomatic Omicron Infection Following a Mass Vaccination Campaign in Southern Brazil: A Prospective Test-Negative Design Study.” Vaccine 41 (37): 5461–68. doi:10.1016/j.vaccine.2023.07.038.